The outbreak of COVID-19 is fueling an urgent need for discovery and development, particularly around medicine, testing and materials – all highly dependent on biology. Many private organizations and government agencies are working together, and teams of scientists across borders are breaking their culture of secrecy and competitive advantage to partner up, openly sharing data to solve major problems fast.
My job as a biologist in the lab used to consist of moving liquids back and forth by hand. At Zymergen, I’m training robots to automate the worst parts of that job, and I’m here to tell you why you should look forward to fully automated luxury science.
Our end-to-end approach for model selection for unsupervised outlier detection algorithms, with an emphasis on parameter tuning.
On Wednesday morning, Zymergen announced our first standalone, commercially available product called HYALINE – a revolutionary bio-generated specialty film in the polyimide family.
Earlier today we announced the release of HYALINE - a revolutionary new bio-fabricated film that we believe will completely transform the electronics industry. Developed in partnership with Sumitomo Chemical, the Hyaline products have been successfully tested in flexible circuits, display touch sensors and printable electronics.
By merging enEvolv’s powerful platform technology with our existing genome engineering, automation and machine learning capabilities, we will dramatically improve our ability to discover, design and commercialize breakthrough biologically-manufactured products.
The World Economic Forum and McKinsey recently published a whitepaper in which they recognize Zymergen as a “lighthouse company”, helping drive what they characterize as the Fourth Industrial Revolution (they also presented us with a lighthouse award, which a number of my colleagues shared from Davos).
At Zymergen, we use biology to create never-before imagined materials. As we continue to scale and build our growing pipeline of next generation products, we’re proud to announce that we’ve appointed Jay Flatley, Chairman of the Board of Illumina, and Sandra E. Peterson, former Group Worldwide Chairman for Johnson & Johnson, to Zymergen’s Board of Directors. Jay will serve as Lead Independent Director.
No one would sell us a high-throughput lab automation system that could be reconfigured in minutes and would scale to fill a factory. So we built one.
An introduction to running parallel tasks with Celery, plus how and why we built an API on top of Celery’s Canvas task primitives.
Subscribe to the Zymergen newsletter.